Key result
Clinical and biochemical criteria effectively diagnose Bartter syndrome without genetic testing in resource-limited settings.
Why the study?
In resource-limited settings where molecular genetic testing is unavailable or unaffordable, clinical and biochemical criteria remain essential for diagnosing Bartter syndrome.
Case Report (n=1)
No
This case demonstrates that Bartter syndrome can be reliably diagnosed and effectively treated with indomethacin using clinical and biochemical criteria in resource-limited settings where genetic testing is unavailable.
Answers are grounded in this paper and cite their sources.
May aid Bartter syndrome diagnosis in resource-limited settings; hypothesis-generating and requires prospective validation before practice change.
Bartter syndrome (BS) is a rare inherited salt-losing tubulopathy characterized by hypokalemic hypochloremic metabolic alkalosis with normotensive hyperreninemic hyperaldosteronism. The disorder results from defective sodium chloride reabsorption in the thick ascending limb of Henle's loop and/or distal convoluted tubule. While genetic testing provides definitive diagnosis, clinical and biochemical criteria remain the cornerstone of diagnosis in resource-limited settings where molecular testing is unavailable or unaffordable.
No takes yet. Share an insight, caveat, or question.
Umesh Joshi (2025) conducted a case report in Bartter syndrome (n=1). Indomethacin was evaluated on Resolution of symptoms and normalization of serum potassium. Indomethacin therapy at 2 mg/kg/day resolved chronic diarrhea within 72 hours and normalized serum potassium within one week in an infant with clinically diagnosed Bartter syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: